secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001437749-25-015514
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma swings to Q1 profit; NERLYNX revenue up 7% to $43.1M
---------------------------------------------------------

- GAAP net income $3.0M ($0.06 EPS) vs net loss $4.8M ($0.10 loss) in Q1 2024.
- Non-GAAP adjusted net income $5.0M ($0.10 EPS) vs adjusted loss $2.4M.
- Product revenue $43.1M (+7% YoY), royalty revenue $2.9M.
- Q2 2025 guidance: net product revenue $48-50M, net income $4-6M.
- Cash & securities $93.2M at Mar 31, down from $101.0M at Dec 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/0001437749-25-015514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/pbyi20250303_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-015514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer